Prevalence of HIV-1 Integrase Strand Transfer Inhibitor Resistance in Treatment-Naive Voluntary Counselling and Testing Clients by Population Sequencing and Illumina Next-Generation Sequencing in Taiwan.
Result: The most common RAMs to NRTIs were M184V and K65R (1.3%), while those for NNRTIs were V179D (4.5%), V106I (2.7%), and K103N (1.3%), and those for PIs were L10I (13.4%), A71T (5.8%), and L10V (4.0%).
Figure: The figure shows that the most common drug resistance-associated mutations were M184V (1.3%) and K65R (1.3%) for NRTIs, V179D (4.5%), V106I (2.7%) and K103N (1.3%) for PMID: 32280691
2020
BioMed research international
Result: The most frequent mutations were L10I/V (32), A71I/T/V (28), and K20I/R (26), among which L10I/V and A71I/T/V are mutations that do not affect drug susceptibility and K20I/R were predicted to have potential resistance to NFV.
Discussion:
Discussion: In this study, among the PI-associated DR mutations detected, K20I/R and T74S were mainly found in CRF01_AE while A71I/T/V, Q58E, and V82I were frequently observed in CRF07_BC, indicating that the presence of different mutations may vary among different subtypes.
HIV Viral Rebound Due to a Possible Drug-Drug Interaction between Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide and Calcium-Containing Products: Report of 2 Cases.
PMID: 30798679
2019
Journal of the International Association of Providers of AIDS Care
Conclusion: The genotype at this time demonstrated no reverse transcriptase (RT) gene mutations, but the following protease gene mutations: L10V, M36I, L63P, H69H/Y, A71T/A, and I93L.
HIV-1 infection among crack cocaine users in a region far from the epicenter of the HIV epidemic in Brazil: Prevalence and molecular characteristics.
Abstract: Five isolates had secondary mutations to protease inhibitors (K20M, L10V, L33I, A71T, A71V).
Result: No major mutation to PI was identified; however, five isolates presented minor PI mutations (K20M: BRGO_CK4, subtype B; A71V: BRGO_CK600, subtype B; L10V: BRGO_CK496, subtype B; A71T and L33I: BRGO_CK311, subtype B; L10V: BRGO_CK117, subtype C).
Research on the treatment effects and drug resistances of long-term second-line antiretroviral therapy among HIV-infected patients from Henan Province in China.
Result: No major resistance to PIs was detected in our study; minor drug resistance to the PIs, A71V/T and L10I, were detected during second-line therapy.
The infection staging and profile of genotypic distribution and drug resistance mutation among the human immunodeficiency virus-1 infected blood donors from five Chinese blood centers, 2012-2014.
Discussion: Perhaps a result that some polymorphic accessory mutations such as: A71V/T and L10I/V on PIs; V106I and V90I on NNRTIs, commonly observed in previous studies, were no longer classified as PI minor DRMs and NNRTI resistance mutations in the updated Stanford HIVdb Program Genotypic Resistance Interpretation Algorithm (HIVdb version 8.3).
Etravirine combined with antiretrovirals other than darunavir/ritonavir for HIV-1-infected, treatment-experienced adults: Week 48 results of a phase IV trial.
HIV mutation literature information.
PMID: 
2020
Infection and drug resistance
Browser Board
Co-occurred Entities
Filtrator
ViMRT